{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:23:33Z","timestamp":1789593813957,"version":"build-2803163510"},"reference-count":44,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004046","name":"Karen Elise Jensen Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004046","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005747","name":"A.P. M\u00f8ller Foundation","doi-asserted-by":"crossref","award":["L-2023-00307"],"award-info":[{"award-number":["L-2023-00307"]}],"id":[{"id":"10.13039\/501100005747","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: In acute myeloid leukemia (AML), the most sensitive measurable residual disease (MRD) methods are single-gene approaches, but these are applicable only in ~60% of AML cases. Methods: We applied multi-omics single-cell analysis on diagnostic and first remission samples to identify leukemia-specific molecular markers for subsequent MRD monitoring in six AML patients lacking AML-defining variants. Results: Five selection criteria were defined to identify suitable MRD markers. Markers of primordial leukemic clones were identified by combining data from single-cell sequencing and immunophenotyping. Specific markers suitable for use in MRD follow-up were identified in 6\/6 patients, in some cases in myelodysplasia-related genes and clonal hematopoiesis-related genes usually not recommended for use in MRD determinations. Patient-specific ddPCR (limits of detection: 0.06\u20130.0011%) or EC-NGS assays correlated with therapeutic responses: 0\/4 markers displayed molecular relapses in three non-relapsing patients, contrary to 4\/4 markers of three relapsing patients. Of these, 3\/4 and 1\/4 markers detected molecular relapses earlier than or simultaneous with conventional methods, respectively (\u2212115 to \u2212338 days). Conclusions: Our results demonstrate that single-cell subclonal mapping at diagnosis and during first remission enables selection of reliable MRD targets for personalized disease surveillance in patients lacking conventional MRD markers.<\/jats:p>","DOI":"10.3390\/cancers18050787","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T16:18:45Z","timestamp":1772554725000},"page":"787","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Single-Cell Multi-Omics Identifies Measurable Residual Disease Targets Among Myelodysplasia- and Clonal Hematopoiesis-Related Genes in Acute Myeloid Leukemia"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4588-5607","authenticated-orcid":false,"given":"Emma Frasez","family":"S\u00f8rensen","sequence":"first","affiliation":[{"name":"Department of Hematology, Aarhus University Hospital, 8200 Aarhus N, Denmark"},{"name":"Department of Clinical Medicine, Aarhus University, 8200 Aarhus N, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2011-3414","authenticated-orcid":false,"given":"Caroline","family":"Arv\u00e9","sequence":"additional","affiliation":[{"name":"Department of Hematology, Aarhus University Hospital, 8200 Aarhus N, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1195-907X","authenticated-orcid":false,"given":"Jonas K.","family":"Gronlund","sequence":"additional","affiliation":[{"name":"Department of Hematology, Aarhus University Hospital, 8200 Aarhus N, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorte","family":"Melsvik","sequence":"additional","affiliation":[{"name":"Department of Hematology, Aarhus University Hospital, 8200 Aarhus N, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2363-9892","authenticated-orcid":false,"given":"Johanne Amalie","family":"Pold","sequence":"additional","affiliation":[{"name":"Department of Hematology, Aarhus University Hospital, 8200 Aarhus N, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6294-2517","authenticated-orcid":false,"given":"Michael","family":"Knudsen","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Aarhus University Hospital, 8200 Aarhus N, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0195-4685","authenticated-orcid":false,"given":"Kasper","family":"Thorsen","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Aarhus University Hospital, 8200 Aarhus N, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anni","family":"Aggerholm","sequence":"additional","affiliation":[{"name":"Department of Hematology, Aarhus University Hospital, 8200 Aarhus N, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7628-8694","authenticated-orcid":false,"given":"Hans Beier","family":"Ommen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Aarhus University Hospital, 8200 Aarhus N, Denmark"},{"name":"Department of Clinical Medicine, Aarhus University, 8200 Aarhus N, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","article-title":"Acute myeloid leukaemia","volume":"401","author":"DiNardo","year":"2023","journal-title":"Lancet"},{"key":"ref_2","unstructured":"RKKP\u2019s Videnscenter (2022). Dansk Akut Leuk\u00e6mi Database & Myelodysplastisk Syndrom Database \u00c5rsrapport 2021, Regionernes Kliniske Kvalitetsudviklingsprogram. Available online: https:\/\/www.sundk.dk\/media\/qxbfayoo\/ald_mds-arsrapport-2021.pdf."},{"key":"ref_3","unstructured":"RKKP\u2019s Videnscenter (2024). Dansk Akut Leuk\u00e6mi Database & Myelodysplastisk Syndrom Database \u00c5rsrapport 2023, Regionernes Kliniske Kvalitetsudviklingsprogram. Available online: https:\/\/www.sundk.dk\/media\/jsjay3ky\/ald_mds-aarsrapport-2023.pdf."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/ajh.25162","article-title":"Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience","volume":"93","author":"Ganzel","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: A consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/hematology.2022000323","article-title":"Achieving MRD negativity in AML: How important is this and how do we get there?","volume":"2022","author":"Hourigan","year":"2022","journal-title":"Hematology"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Cloos, J., Valk, P.J.M., Thiede, C., D\u00f6hner, K., Roboz, G.J., Wood, B.L., Walter, R.B., Wang, S.A., Wierzbowska, A., and Wei, A.H. (2025). 2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party. Blood, Online ahead of print.","DOI":"10.1182\/blood.2025031480"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1002\/ajh.27087","article-title":"Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel","volume":"98","author":"Ravandi","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1016\/S2352-3026(25)00037-7","article-title":"Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: Results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials","volume":"12","author":"Potter","year":"2025","journal-title":"Lancet Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Moritz, J., Schwab, A., Reinisch, A., Zebisch, A., Sill, H., and W\u00f6lfler, A. (2024). Measurable Residual Disease Detection in Acute Myeloid Leukemia: Current Challenges and Future Directions. Biomedicines, 12.","DOI":"10.3390\/biomedicines12030599"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"evidoa2200310","DOI":"10.1056\/EVIDoa2200310","article-title":"Prediction of risk for myeloid malignancy in clonal hematopoiesis","volume":"2","author":"Weeks","year":"2023","journal-title":"NEJM Evid."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1038\/s41467-020-19119-8","article-title":"Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics","volume":"11","author":"Morita","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/bjh.13062","article-title":"Persistence of DNMT3A mutations at long-term remission in adult patients with AML","volume":"167","author":"Nederby","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"eadg0488","DOI":"10.1126\/sciadv.adg0488","article-title":"Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia","volume":"9","author":"Robinson","year":"2023","journal-title":"Sci. Adv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1158\/2643-3230.BCD-21-0046","article-title":"Personalized Single-Cell Proteogenomics to Distinguish Acute Myeloid Leukemia from Non-Malignant Clonal Hematopoiesis","volume":"2","author":"Dillon","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/bloodadvances.2019001181","article-title":"Single-cell mutational profiling enhances the clinical evaluation of AML MRD","volume":"4","author":"Ediriwickrema","year":"2020","journal-title":"Blood Adv."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","article-title":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","volume":"587","author":"Miles","year":"2020","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1200\/JCO.2009.22.4865","article-title":"Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: A European LeukemiaNet study","volume":"27","author":"Cilloni","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/bjh.17449","article-title":"Peripheral blood molecular measurable residual disease is sufficient to identify patients with acute myeloid leukaemia with imminent clinical relapse","volume":"195","author":"Skou","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1093\/bioinformatics\/bty897","article-title":"VarSome: The human genomic variant search engine","volume":"35","author":"Kopanos","year":"2019","journal-title":"Bioinformatics"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/ejh.14151","article-title":"Droplet digital PCR for sensitive relapse detection in acute myeloid leukaemia patients transplanted by reduced intensity conditioning","volume":"112","author":"Gronlund","year":"2024","journal-title":"Eur. J. Haematol."},{"key":"ref_24","unstructured":"Bio-Rad (2025, June 26). ddPCR\u2122 Rare Mutation Detection. Available online: https:\/\/www.bio-rad.com\/webroot\/web\/pdf\/lsr\/literature\/Bulletin_6628.pdf."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1093\/bioinformatics\/btt750","article-title":"Subclonal variant calling with multiple samples and prior knowledge","volume":"30","author":"Gerstung","year":"2014","journal-title":"Bioinformatics"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.3324\/haematol.2022.282034","article-title":"The present and future of measurable residual disease testing in acute myeloid leukemia","volume":"107","author":"Blachly","year":"2022","journal-title":"Haematologica"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000535463","article-title":"Test Then Erase? Current Status and Future Opportunities for Measurable Residual Disease Testing in Acute Myeloid Leukemia","volume":"147","author":"Blackmon","year":"2024","journal-title":"Acta Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1182\/blood.2020010483","article-title":"Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia","volume":"138","author":"Tanaka","year":"2021","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular Minimal Residual Disease in Acute Myeloid Leukemia","volume":"378","author":"Grob","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00432-024-05999-6","article-title":"Prognostic impact of clonal hematopoiesis mutations at complete molecular remission in acute myeloid leukemia with NPM1 mutation","volume":"150","author":"Wang","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41375-022-01647-5","article-title":"Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia","volume":"36","author":"Kramer","year":"2022","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.5001\/omj.2021.108","article-title":"Identifying Leukemia-associated Immunophenotypes in Acute Myeloid Leukemia Patients Using Multiparameter Flow Cytometry","volume":"36","author":"Rasheed","year":"2021","journal-title":"Oman Med. J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/leu.2017.113","article-title":"Measurable residual disease testing in acute myeloid leukaemia","volume":"31","author":"Hourigan","year":"2017","journal-title":"Leukemia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1182\/blood.V124.21.1055.1055","article-title":"Relapse Kinetics in Acute Myeloid Leukemis Cases Encompassing More Than One Common Mutation: Towards a Unified Model","volume":"124","author":"Ommen","year":"2014","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for Myelodysplastic Syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","article-title":"CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial","volume":"8","author":"Lancet","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1200\/JCO.24.00259","article-title":"Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial","volume":"43","author":"Russell","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e180065","DOI":"10.1172\/JCI180065","article-title":"Clonal hematopoiesis and hematological malignancy","volume":"134","author":"Dunn","year":"2024","journal-title":"J. Clin. Invest."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Chow, R.D., Velu, P., Deihimi, S., Belman, J., Youn, A., Shah, N., Luger, S.M., Carroll, M.P., Morrissette, J., and Bowman, R.L. (2024). Early drivers of clonal hematopoiesis shape the evolutionary trajectories of de novo acute myeloid leukemia. medRxiv.","DOI":"10.1101\/2024.08.31.24312756"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/bloodadvances.2021005789","article-title":"Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation","volume":"7","author":"Bill","year":"2023","journal-title":"Blood Adv."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s10014-022-00442-5","article-title":"Clinical application of a highly sensitive digital PCR assay to detect a small fraction of IDH1 R132H-mutant alleles in diffuse gliomas","volume":"39","author":"Satomi","year":"2022","journal-title":"Brain Tumor Pathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"42345","DOI":"10.18632\/oncotarget.5645","article-title":"IDH1\/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: A study by the Acute Leukemia French Association","volume":"6","author":"Debarri","year":"2015","journal-title":"Oncotarget"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41698-024-00528-7","article-title":"Delineating functional and molecular impact of ex vivo sample handling in precision medicine","volume":"8","author":"Struyf","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.2023.283520","article-title":"Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia","volume":"109","author":"Dillon","year":"2024","journal-title":"Haematologica"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/5\/787\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T05:11:50Z","timestamp":1772687510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/5\/787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["cancers18050787"],"URL":"https:\/\/doi.org\/10.3390\/cancers18050787","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]}}}